Background Image
Biomet
One Surgeon. One Patient.
 
Cellentra™ VCBM (Viable Cell Bone Matrix)

Cellentra™ VCBM (Viable Cell Bone Matrix)

The Complete Bone Remodeling Triad

  • Viable Osteogenic Cells: = 250,000 cells per cc including mesenchymal stem cells (MSCs), osteoprogenitor cells and pre-osteoblasts
  • Verified Osteoinductivity: Demineralized component provides additional inherent growth factors. Demineralized bone has been shown to include BMP-2, 4, 7, VEGF, TGF-ß, PDGF, IGF-1, FGF1, 2, 3
  • Osteoconductive Scaffold: Cancellous bone matrix offers an interconnected trabecular structure

Excellent Safety Profile

  • Cellentra™ VCBM test samples were shown to be immuno-protective and immuno-suppressive*, **
  • Processed via stringent donor screening, testing and sterility procedures

Optimal Handling

  • Graft composition designed to provide superior handling
  • Consistent graft-packing capabilities
  • Syringe delivery may facilitate controlled graft placement

1. W.S. Pietrzak, J. Woodell-May, N. Mcdonald. Assay of Bone Morphogenetic Protein -2, -4 and -7 in Human Demineralized Bone Matrix. J. Craniofac Surg. 2006 Jan;17(1):84.90.***
2. B. Wildemann, A. Kadow-Romacker, N.P. Haas, G. Schmidmaier. Quantification of Various Growth Factors in Different Demineralized Bone Matrix Preparations. J. Biomed Mater Res A. 2007 May;81(2):437-42.
3. B. Blum, J. Moseley, L. Miller, K. Richelsoph, W. Haggard. Measurement of Bone Morphogenetic Proteins and Other Growth Factors in Demineralized Bone Matrix. Orthopedics. 2004 Jan;27(1Suppl): S161-5.

* Data on File
** In vitro cellular and pre-clinical studies may not be indicative of human clinical outcomes.
*** FINANCIAL: In support of their research or for preparation of this work, one or more of the authors received financial remuneration from Biomet, EBI, LLC or Bioelectron, Inc.

Additional Information

Patient Risk Information - LD64-1000
PDF File - 393 KB

 

© Copyright 2014 Biomet, Inc. All rights reserved.
Background Image